Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib Dose Escalation in Metastatic GIST
NCT01031628Phase 3Terminated
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Start
- Jan 2010
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of imatinib in gastrointestinal stromal tumor (GIST) (4 arms), sponsored by Sarcoma Alliance for Research through Collaboration. Primary endpoint: Evaluation of Lesions for Progression or Response Via RECIST Criteria. Started Jan 2010; status: terminated.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT01031628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01031628.